Reputation how can you have an impact? Stefaan Fiers, PhD - PDF document

(C)St. Fiers - BeAPP presentation 2/3/2018 Reputation – how can you have an impact? Stefaan Fiers, PhD Communications & Public Policy Director, pharma.be ste_fiers pharmabe While we are all patient centric 1

(C)St. Fiers - BeAPP presentation 2/3/2018 Instead, we can help to refocus the debate on • Our mission • Medical progress • Health is wealth • Health in all policies • CSR • … The value of medicines Our mission : More than 7,000 treatments in development 2

(C)St. Fiers - BeAPP presentation 2/3/2018 The benefit of medical & pharmaceutical progress Medicines are some of the most powerful tools in treating and curing deadly diseases Hepatitis C Virus (HCV): HCV, which is the leading cause of liver transplants and the reason liver cancer is on the rise, is now curable in more than 90% of treated patients with only 8-12 weeks of treatment . +133% cure rate increase for patients 2 8-12 15 12 Weeks* Weeks* million 100% 24-48 people are Weeks* living with 75% 48 95-96% Cure Rate 90% Hepatitis C Weeks* cure rate cure rate 50% in Europe 1 63-80% cure rate 25% 41% cure rate 0% 1st generation 2nd generation 3rd generation 4th generation (2014- 1st generation (2001-2010) 2nd generation (2011-2013) 3rd generation (2013-2014) 4th generation (2014-2015) (1999-2010) (2011-2013) (2013-2014) Polymerase 2015) Interferon and Ribavarin Protease Inhibitors Polymerase Inhibitors Combination Therapies Interferon and Ribavarin Protease Inhibitors w/ Inhibitors w/ IFN Injection Oral Combination (IFN-R) Injection IFN Injection Therapies * Treatment duration. Note: EMA approval dates. Cure rates are based on the results of clinical trials reported by the US Food and Drug Administration (FDA) for different drugs against Hepatitis C. Source: Health Advances analysis; 1 Hope 2014 Prevalence and estimation of hepatitis B and C infections in the WHO European region Epidemiol Infect; European Medicines Agency (EMA) website; 2 EFPIA 2015 Health & Growth Evidence Compendia analysis of PhRMA 2014 25 Years of Progress Against Hepatitis C and PhRMA 2015 Pharma Profile. 3

(C)St. Fiers - BeAPP presentation 2/3/2018 R&D is very capital intensive The development of a medicine is long, demanding and risky. A new medicine can be developed within 10 to 15 years. � Resources are needed today to fund R&D-activities for new and wanted medicines in the future. 4

(C)St. Fiers - BeAPP presentation 2/3/2018 The pharma business model Obtaining the required resources, from sales and investors, to invest and take risks on a long term in order to allow innovation. This is at the core of the pharma business model. - Profits? - Yes. - Why? 5

(C)St. Fiers - BeAPP presentation 2/3/2018 Profits in the pharmaceutical industry are not out of line with comparable high risk knowledge-intensive sectors. pharma is only 13% of the healthcare budget and contributes most to savings 6

(C)St. Fiers - BeAPP presentation 2/3/2018 The pharma valley in Belgium A unique ecosystem of multinational corporations, biotechnological companies and specialist SMEs 2 airports with CEIV certification: Brussels & Liège pharma.be members only 13 Pharma figures 2016 : Belgium, a growing pharmaceutical hub 14 7

(C)St. Fiers - BeAPP presentation 2/3/2018 Belgium, a European leader in pharma 2 nd in export of 2 nd in R&D medicines spending € 40,7 Bn €2,89 Bn 4 th in pharma 2 nd in R&D employment employment 35.250 employees 4.472 researchers 15 Weighting based on the relative share of each country in the total EU population Belgium, #2 in EU in clinical research Belgium holds a remarkable position in the EU , with: Belgium is at the forefront of novel medical techniques , with: 16 8

(C)St. Fiers - BeAPP presentation 2/3/2018 #WijGevenNietOp – #LeCombatContinue 9

(C)St. Fiers - BeAPP presentation 2/3/2018 #We Wont Rest – are you? • Please join us in this campaign • And become a proud ambassador of the pharma industry • Send your picture • and your ‘pledge’ (max 250 characters) to Gregory Willocq of pharma.be gw@pharma.be #LeCombatContinue -#WijGevenNietOp Like us, share our info pharmabe ste_fiers https://www.linkedin.com/company/pharma-be/ 10

(C)St. Fiers - BeAPP presentation 2/3/2018 Thank you ! e: sf@pharma.be m: 0476-769077 t: ste_fiers 11